EmergingCognitiveLongevity

Adamax

Next-Generation Semax Derivative | Nootropic Neuropeptide

Half-life

8-10 hours

Chain length

Not reported

Reference frequency

Once daily, or twice for enhanced neuroprotection

Research overview

DoseGear research brief

Synthetic nootropic peptide with N-terminal acetylation and C-terminal adamantane modification for superior stability and blood-brain barrier penetration, researched for cognitive enhancement, neuroprotection, and neuroplasticity.

Mechanism of action

Crosses BBB via enhanced lipophilicity from adamantane; upregulates BDNF and TrkB receptor sensitivity; modulates dopamine, norepinephrine, and serotonin; stabilizes microtubules via ADNP-derived mechanisms; provides antioxidant and anti-inflammatory neuroprotection.

Compound background

Development & research timeline

Study windows describe what researchers measured, not when an individual should expect a result.

Origin & development

Acetylated, adamantane-modified nootropic peptide related to Semax; a specific developer is not established.

What it is researched for

Proposed cognition and neuroprotection research involving stability, brain delivery, and neurotrophic signaling.

Research observation window

Not reported in the reviewed compound-specific evidence. Semax findings cannot establish an Adamax response window.

Reference data

Lyophilized vial injectable protocols

Not personalized dosing instructions

Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.

Research context	Amount	Frequency	Route
Cognitive Enhancement	200-300mcg	1x daily	SubQ
Neuroprotection	300mcg	1-2x daily	SubQ
Mood Support	200mcg	1x daily (morning)	SubQ
Initial Trial	100-200mcg	1x daily	SubQ

Reference cycle

2-4 weeks

Reference storage

Lyophilized: room temp or freezer; Reconstituted: 2-8°C for 14-30 days

Safety context

Reported side effects

Headaches (particularly at higher doses)
Insomnia or sleep disruption
Anxiety or overstimulation
Cardiovascular effects (elevated blood pressure, palpitations)

Contraindications & cautions

Pregnancy and breastfeeding
Cardiovascular conditions (without medical supervision)
Severe anxiety disorders
Uncontrolled hypertension

Scientific references

01
A Nootropic Adrenocorticotropin Analog 4-10 Semax: 15 Years Experience in Its Design and Study (Parent Compound)
Scientific citationA Nootropic Adrenocorticotropin Analog 4-10 Semax: 15 Years Experience in Its Design and Study (Parent Compound). Zhurnal Vysshei Nervnoi Deiatelnosti imeni I.P. Pavlova (1997).
02
Semax, an Analog of ACTH(4-10), Regulates BDNF and trkB Expression in the Rat Hippocampus (Parent Compound)
Scientific citationSemax, an Analog of ACTH(4-10), Regulates BDNF and trkB Expression in the Rat Hippocampus (Parent Compound). Brain Research (2006).
03
The Efficacy of Semax in the Treatment of Patients at Different Stages of Ischemic Stroke (Parent Compound)
Scientific citationThe Efficacy of Semax in the Treatment of Patients at Different Stages of Ischemic Stroke (Parent Compound). Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova (2018).
04
The Peptide Semax Affects the Expression of Genes Related to the Immune and Vascular Systems in Rat Brain Focal Ischemia (Parent Compound)
Scientific citationThe Peptide Semax Affects the Expression of Genes Related to the Immune and Vascular Systems in Rat Brain Focal Ischemia (Parent Compound). BMC Genomics (2014).

This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.

Related research profiles

Longevity